Imagion Biosystems just removed the final procedural barrier to initiating its planned Phase 2 clinical study for MagSense in HER2+ breast cancer. The company has secured IND clearance from the FDA in an achievement that is the company’s most important to date from a regulatory perspective and is an endorsement of its efforts.

MagSense promises better cancer diagnostics

MagSense is positioned as a superior imaging agent, not just because of parity or outperformance compared to existing agents, but it works with a lower radiation dose and is capable of detecting tumours earlier than conventional imaging as well as confirming tumours (something usually only possible by removing tissue from the body). Why? Because the ‘contrast’ created by the iron particles is differentiated from normal tissue when the MagSense® agent binds to their target. Detecting cancers earlier will enable more effective treatment options.

If Phase 2 is anything like Phase 1, there will be commercial interest

Imagion’s study is expected to take 18–24 months and should provide insights beyond diagnostic accuracy, including workflow integration, cost‑of‑care implications and the potential for AI‑ready imaging data. If the Phase 1b/2 results replicate what was shown in Phase 1, be positioned to pursue a licensing‑led model in HER2+ breast cancer. A partner could take MagSense through a potential Phase 3 study (if required), scale manufacturing and integrate the agent into MRI workflows. It could also help with MagSense’s eventual commercialisation.

A valuation of A$0.10-0.12 is our base case, but even further upside is possible

Imagion’s share price and volume rise following yesterday’s IND announcement is a sign investors are realising MagSense’s potential, but we believe there is still upside to come. Our valuation was and remains $0.10-0.12 per share, representing market capitalisations of $46.6m and $56.5m respectively. It assumed MagSense is commercialised against HER2 breast cancer, under a licensing and royalty-based model, but could be the tip of the iceberg as it did not account for further indications – our previous notes have outlined the further upside possible. We intend to write a more comprehensive update in the coming days.